Myelofibrosis Bone Marrow Mononuclear Cells

Myelofibrosis Bone Marrow Mononuclear Cells for Hematology Research

Our Myelofibrosis Bone Marrow Mononuclear Cells is a hematopoietic tissue sample isolated by density-gradient separation from bone marrow aspirate, capturing the full spectrum of marrow-resident hematopoietic stem, progenitor, and precursor cells that peripheral blood samples do not contain. Samples are sourced from IRB-consented donors clinically diagnosed with myelofibrosis, a myeloproliferative neoplasm characterized by progressive marrow fibrosis.

Myelofibrosis Biology and Why Bone Marrow

• Myelofibrosis is defined by progressive replacement of normal hematopoietic marrow with fibrotic tissue, driven by clonal hematopoietic stem cells and abnormal megakaryocyte-derived cytokine signaling.
• Bone marrow biopsy is essential for diagnosis and for grading reticulin and collagen fibrosis, a central component of WHO diagnostic criteria that cannot be assessed from peripheral blood.
• Driver mutations in JAK2, CALR, or MPL are present in the majority of cases and are assessed alongside marrow histology for diagnosis and prognostic scoring.
• JAK inhibitor therapy (e.g. ruxolitinib, fedratinib) is the mainstay of symptom management, and marrow-derived material supports pharmacodynamic and resistance research.
• Progressive marrow failure and extramedullary hematopoiesis are hallmark features under active investigation, along with the mechanisms driving transformation to acute leukemia in a subset of patients.

Donor Stratification Available

• Driver mutation status: JAK2, CALR, or MPL
• Marrow fibrosis grade where documented
• Prognostic risk category (e.g. DIPSS) where documented
• Treatment history, including JAK inhibitor exposure or transplant
• Age band and sex assigned at birth
• Matched healthy bone marrow controls available

Product Features

• Isolated from clinically confirmed myelofibrosis donor bone marrow aspirate
• Density-gradient purified and cryopreserved
• Research Use Only (RUO)
• IRB-approved protocols with documented consent
• Standard and custom cell quantities available

De-identified Donor Data

• Myelofibrosis diagnosis confirmation and driver mutation status where documented
• Age, sex assigned at birth, and ethnicity
• Donor-reported allergy and infectious disease history
• Treatment history and fibrosis grade where documented
• Additional myelofibrosis-specific metadata available on request

Applications

• JAK2, CALR, and MPL driver mutation studies
• JAK inhibitor pharmacodynamic and resistance research
• Marrow fibrosis mechanism and progression studies
• Extramedullary hematopoiesis research
• Leukemic transformation biomarker studies

Other Specimen Types

For matched marrow-derived material across conditions, see our human bone marrow mononuclear cells collection.

Compliance and Quality Assurance

• IRB-approved and HIPAA-compliant protocols
• Electronic informed consent with 21 CFR Part 11-compliant e-signatures
• Documentation support available for regulatory review

Ordering & Customization

Myelofibrosis bone marrow mononuclear cells are available in standard and custom cell quantities. For pricing, international orders, or documentation requirements, please email learnmore@sanguinebio.com to ensure compatibility with your country’s regulations.